

RESEARCH

Open Access



Exploration of the mechanism by which Huangqi Guizhi Wuwu decoction inhibits Lps-induced inflammation by regulating macrophage polarization based on network pharmacology

Sutong Wang^{1†}, Tianshu Ji^{1†}, Lin Wang^{1†}, Yiwei Qu¹, Xinhui Wang¹, Wenting Wang², Mujie Lv¹, Yongcheng Wang³, Xiao Li³ and Ping Jiang^{3*}

Abstract

Background Huangqi Guizhi Wuwu decoction (HQGZWWD) is a traditional Chinese herbal medicine formulation with significant anti-inflammatory activity. However, its underlying mechanism remains unknown. Through network pharmacology and experimental validation, this study aimed to examine the potential mechanism of HQGZWWD in regulating macrophage polarization and inflammation.

Methods The active components were obtained from the Traditional Chinese Medicine Systems Pharmacology database and Analysis Platform (TCMSP), whereas the corresponding targets were obtained from the TCMSP and Swiss Target Prediction database. The GeneCards database identified targets associated with macrophage polarization and inflammation. Multiple networks were developed to identify the key compounds, principal biological processes, and pathways of HQGZWWD that regulate macrophage polarization and inflammation. Autodock Vina is utilized to assess the binding ability between targets and active compounds. Finally, confirm the experiment's central hypothesis. Human histiocytic lymphoma (U-937) cells were transformed into M1 macrophages following stimulation with Lipopolysaccharide (LPS) to evaluate the effect of HQGZWWD drug-containing mouse serum (HQGZWWD serum) on regulating macrophage polarization and inflammation.

Results A total of 54 active components and 859 HQGZWWD targets were obtained. There were 9972 targets associated with macrophage polarization and 11,109 targets associated with inflammation. After screening, 34 overlapping targets were identified, of which 5 were identified as central targets confirmed by experiments, including the $\alpha 7$ nicotinic acetylcholine receptor ($\alpha 7$ nAChR), interleukin 6 (IL-6), Interleukin-1 beta (IL-1 β), interleukin 10 (IL-10) and growth factor beta (TGF- $\beta 1$). Pathway enrichment analysis revealed that 34 overlapping targets were enriched in multiple pathways associated with macrophage polarization and inflammation, including the TGF beta signaling pathway, NF-kappa B signaling pathway, JAK-STAT signaling pathway, and TNF signaling pathway. Molecular docking confirmed

[†]Sutong Wang, Tianshu Ji and Lin Wang contributed equally to this work.

*Correspondence:

Ping Jiang

lmdlmd6617@163.com

Full list of author information is available at the end of the article



that the majority of HQGZWWDD's compounds can bind to the target. In vitro experiments, HQGZWWDD serum was shown to up-regulate the expression of $\alpha 7$ nAChR, reduce the number of M1 macrophages, stimulate the production of M2 macrophages, inhibit the expression of pro-inflammatory cytokines IL-6 and IL-1 β , and increase the expression of anti-inflammatory cytokines IL-10 and TGF- $\beta 1$.

Conclusion HQGZWWDD can regulate the number of M1/M2 macrophages and the level of inflammatory cytokines, and the underlying mechanism may be related to the up-regulation of $\alpha 7$ nAChR expression.

Keywords Huangqi Guizhi Wuwu decoction, Macrophage polarization, Inflammation, $\alpha 7$ nAChR

The inflammatory response is a dynamic evolutionary tissue defense response against pathogens that infiltrate the organism and involves a complex series of processes including phagocytosis, release of inflammatory factors, and chemokines, which are responsible for destroying and clearing pathogens [1]. Currently, NSAIDs and glucocorticoids are the most prevalent anti-inflammatory medications, and their long-term use carries a variety of risks, including gastrointestinal reactions and immunosuppression [2, 3]. As a result, many studies have focused on inflammation regression as a novel approach to treating inflammatory diseases.

Macrophages are an essential component of the body's intrinsic immunity [4], which can respond to local micro-environmental changes by reprogramming their metabolic and polarizing phenotypes, and their phenotypic transformation is a crucial step in the regression of inflammation. In general, macrophages are divided into two types: 1) Classical activated or M1 macrophages, which can be activated by Lipopolysaccharide (LPS) and interferon- γ (IFN- γ), secrete primarily pro-inflammatory factors such as interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF- α) [5, 6]; and 2) Alternatively activated or M2 macrophages, which can be activated by interleukin 4 (IL-4) \interleukin 13 (IL-13), secrete primarily anti-inflammatory factors such as interleukin 10 (IL-10) and growth factor beta (TGF- $\beta 1$) to promote tissue repair [7–9].

Huangqi Guizhi Wuwu decoction (HQGZWWDD) is a traditional Chinese herbal formula based on Zhongjing Zhang's "Synopsis of the Golden Chamber" and consists of *Hedysarum multijugum* Maxim. (Huangqi, HQ),

Cinnamomi ramulus (Guizhi, GZ), *Paeoniae radix alba* (Baishao, BS), *Zingiber officinale roscoe* (Shengjiang, SJ), and *Jujubae fructus* (Dazao, DZ), details of each herb are shown in Table 1. HQGZWWDD is effective in treating peripheral neuropathy (PN) [10–12] and rheumatoid arthritis (RA) [13, 14]. In recent years, many studies have shown that the imbalance between M1 macrophages and M2 macrophages contributes to the progression of PN and RA [15, 16], such as inducing M1 macrophages to M2 macrophages, inhibiting M1 macrophage inflammatory cytokines TNF- α , IL-1 β , and IL-6 expression, and increasing M2 macrophage anti-inflammatory factor IL-10 expression is beneficial to the repair of peripheral nerve injury [17], and delay the progression of RA [18–20]. According to previous pharmacological studies, HQGZWWDD can down-regulate levels of pro-inflammatory cytokines IL-1 β , IL-6, and TNF- α in serum from rats with neuropathic pain induced by oxaliplatin, inhibit MAPK pathway, down-regulate the expression of NF-kappa B (NF- κ B), and repair nerve cell injury [21]. The treatment of RA rats with HQGZWWDD can up-regulate the level of anti-inflammatory cytokines IL-4 and IL-10 in serum, down-regulate the level of pro-inflammatory cytokines IL-1 β , IL-6, and TNF- α , and reduce the expression of NF- κ B in synovial tissue [22]. It can be demonstrated that HQGZWWDD has strong anti-inflammatory activity, which can inhibit the levels of pro-inflammatory cytokines IL-1 β and IL-6 secreted primarily by M1 macrophages and up-regulate the level of anti-inflammatory cytokines IL-10 secreted primarily by M2 macrophages. These results show that the anti-inflammatory impact

Table 1 Details of the ingredients of Huangqi Guizhi Wuwu Decoction

Scientific species names	Family	Medicinal parts	Name	Chinese name	Specimen number
<i>Hedysarum multijugum</i> Maxim.	Leguminosae	root	<i>Astragali Radix</i>	Huangqi	210,861,942
<i>Cinnamomum cassia</i> (L.) J.Presl	Lauraceae	twig	<i>Cinnamomi ramulus</i>	Guizhi	210,741,832
<i>Paeonia lactiflora</i> Pall.	Paeoniaceae	root	<i>Paeoniae radix alba</i>	Baishao	210,960,876
<i>Zingiber officinale</i> Rosc.	Zingerberaceae	rhizome	<i>Zingiberis Rhizoma Recens</i>	Shengjiang	210,231,903
<i>Ziziphus jujube</i> Mill.	Rhamnaceae	fruit	<i>Jujubae fructus</i>	Dazao	210,652,610

of HQGZWWD in PN and RA may be associated with the regulation of M1/M2 macrophage phenotypic transformation. In a previous study, we found that the herbal combination including HQ could improve the inflammatory response and reduce atherosclerosis in ApoE^{-/-} mice via controlling the balance between M1/M2 macrophages [23]. Recent studies [24–26] have demonstrated that Astragaloside IV (AS-IV), the active component of HQ, and total glucosides of paeony, the active component of BS, suppress the polarization of M1 macrophages and exert anti-inflammatory activity. In previous investigations, we have observed that AS-IV can reduce the levels of IL-1 β and TNF- α in the hypothalamus of obese and hypertensive rats and reduce inflammation [27]. In another series of studies, we found that the combination of GZ, BS, SJ, and DZ in HQGZWWD can decrease the level of IL-6 and IL-1 β in the myocardium of hypertensive rats, increase the level of IL-10 and TGF- β 1, inhibit myocardial fibrosis [28, 29], and decrease the level of NF- κ B in spontaneously diabetic rats [30]. These results demonstrate that the anti-inflammatory effect of HQGZWWD is supported by extensive experimental and clinical evidence and has tremendous promise for regulating macrophage polarization. However, the anti-inflammatory mechanism of HQGZWWD and its active components are not fully understood at present. The regulation of the phenotypic transformation of M1/M2 macrophages by HQGZWWD is not well studied. Additional study is required to enhance its anti-inflammatory mechanism and offer scientific evidence for future therapeutic application.

The content of prescribed medications for traditional Chinese medicine (TCM) is complex, and the intended effect and underlying process are unknown. Compared to modern medicine, it is challenging to conduct systematic and exhaustive research at the cellular and molecular levels. Integrating data such as genes, proteins, and information pathways [31], systems biology develops mathematical models that describe the structure of biological systems and their responses to individual disturbances. Based on the methods of system biology, Shao Li [32] introduced the concept of network pharmacology. Network pharmacology tends to demonstrate integrity and systematicity that are consistent with fundamental TCM theories, for example, the holistic view and syndrome differentiation, which are a means of explaining the relationship between drugs, targets, and diseases systematically. As a result, it is more conducive to revealing the intricate characteristics of TCM prescriptions to provide a scientific basis for a comprehensive examination of these prescriptions. Through network pharmacology, some studies have clarified the mechanism of HQGZWWD in the treatment of rheumatoid arthritis [33], peripheral

neurotoxicity [34], and colon cancer [35]. These pieces of evidence suggest that network pharmacological analysis may be a good tool to explore the relationship between effective components of HQGZWWD and macrophage polarization.

To elucidate the anti-inflammatory mechanism of HQGZWWD, we employed network pharmacology in conjunction with molecular docking and in vitro experiments to examine the regulatory effect of HQGZWWD on macrophage polarization. The detailed flowchart is depicted in Fig. 1.

Materials and methods

Identification of active ingredients and prediction of corresponding targets of Huangqi Guizhi Wuwu decoction

The Traditional Chinese Medicine Systems Pharmacology database and Analysis Platform (TCMSP) (<http://lsp.nwu.edu.cn/tcmsp.php>) was utilized to screen the active ingredients in HQGZWWD based on its recommended drug screening criteria of oral bio-availability (OB) \geq 30% and drug-likeness (DL) \geq 0.18. Files containing the 2D structures of the active ingredients were saved. Combining the TCMSP database with the SwissTargetPrediction (STP) (<http://www.swisstargetprediction.ch/>) yielded the targets corresponding to the active ingredients, where the inclusion criterion for targets derived from the STP was Probability $>$ 0.

Identification of macrophage polarization-related targets and inflammation-related targets

Using the search terms “Macrophage polarization” and “inflammation” on Gene Cards (<https://www.genecards.org/>), targets associated with macrophage polarization and inflammation were identified. By mapping Venn diagrams using the OmicStudio online platform (<http://www.omicstudio.cn/tool>), intersection targets of active ingredient-related targets, macrophage polarization-related targets, and inflammation-related targets were identified, which could serve as potential targets for HQGZWWD in regulating macrophage polarization and inflammation. To verify the reliability of the intersection target, we searched the data set GSE127981 for transcriptome sequencing of M1/M2 macrophages induced by U937 cells from the GEO database, compared the expression of the intersection target, normalized the data [36], and drew a heat map.

Analyses of gene ontology and pathway enrichment

R language [37] (clusterProfiler, AnnotationHub, org.Hs.eg.db, ggplot2, and DOSE) was used to analyze gene ontology (GO) function enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway




Fig. 1 Flowchart of the study

enrichment [38–40]. The component-target-pathway (C-T-P) network is then constructed using Cytoscape 3.8.1 software. The GO terms and KEGG terms with a p -value < 0.05 were considered significantly enriched.

Construction of the protein-protein interaction network

To construct a PPI network, the intersection targets of HQGZWW, macrophage polarization, and inflammation were imported into the STRING database (<https://string-db.org/>), the species was set to “*Homo sapiens*”, and the confidence score was set to > 0.4 [41]. The resulting network was imported into Cytoscape 3.8.1, and its targets were scored with the cytoHubba plugin and MCC algorithm [42].

Molecular docking

We mapped 34 targets to 51 components for molecular docking. Obtaining Protein 3D Structure from PDB Database (<http://www.pdb.org/>), and saved as a PDB file, while the active ingredient structure is obtained from PubChem (<https://pubchem.ncbi.nlm.nih.gov>) and saved as a mol2 file. PyMOL 2.4.1 software is used to remove water and ligands from proteins, and AutodockVina 1.1.2 [43] software is used to hydrogenate target proteins, calculate charges, and ChemOffice 22 Professional software is used to minimize the energy of small molecular compounds. In the process of molecular docking, some target proteins have corresponding targeted small molecules. For these proteins, we use GetBox-PyMOL-Plugin in Pymol2.4.1 to obtain the binding pockets corresponding to targeted small molecules for the next docking step. For proteins that do not target small molecules but have eutectic ligands, the binding pockets corresponding to the ligands can be obtained for the next docking of molecules. For proteins that do not target small molecules or eutectic ligands, we used blind docking. Molecular docking is performed through AutodockVina 1.1.2. The docking score is used to evaluate the binding ability between the target and the component. Details and parameter settings of molecular docking are shown in Table 2.

Preparation of Huangqi Guizhi Wuwu decoction drug-containing mouse serum

The herbal medicines were purchased from the herbal pharmacy of the Affiliated Hospital of Shandong University of Traditional Chinese Medicine (Jinan, China), and the quality was agreed upon with the People's Republic of China Pharmacopoeia (2020). They were verified by Prof. Xueshun Zhang, and voucher specimens were deposited at TCM Pharmacy of Affiliated Hospital of Shandong University of Traditional Chinese Medicine (Jinan, China). Specimen numbers are presented in Table 1. HQGZWW was made of *Hedysarum multijugum*

Maxim. (Chinese herbs pieces, Catalog No. 2108230112, Anhui Bozhou Huqiao Pharmaceutical Co., Ltd.), *Cinnamomi ramulus* (Chinese herbs pieces, Catalog No. 220501, BWT Chinese Herbal Medicine Drinks Slice Co., Ltd.), *Paeoniae radix alba* (Chinese herbs pieces, Catalog No. 2106220172, Anhui Bozhou Huqiao Pharmaceutical Co., Ltd.), *Zingiber officinale roscoe* (Chinese herbs pieces, Catalog No. 2108180152, Anhui Bozhou Huqiao Pharmaceutical Co., Ltd.) and *Jujubae fructus* (Chinese herbs pieces, Catalog No. 2106140092, Anhui Bozhou Huqiao Pharmaceutical Co., Ltd.) in the standard ratio of 1:1:1:1:1. 10 times the volume of distilled water is added, and the mixture is decocted twice for 1 hour each time. The solutions were combined and concentrated to a relative density of 1.20 to 1.25 (70°C to 80°C), dispensed, and stored at 4°C. Specific pathogen-free (SPF) grade male C57BL/6J mouse, 6 weeks of age, 20 g to 25 g in body weight, acquired from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China, Certificate No. SCXK-2016-00). They were randomly divided into serum-containing and serum-free groups. With free access to food and water, the mice are housed at 24°C with constant humidity and a diurnal light cycle on a normal diet. After 2 weeks of feeding, the serum-containing groups received HQGZWW for 5 days (5.2 g/kg/day), while the serum-free groups received the same volume of stroke-physiological saline solution. Each mouse was anesthetized by an intraperitoneal injection of 4% pentobarbital sodium 1 hour after the final administration. Blood samples were collected from the retro-orbital plexus, left at room temperature for 2 hours, and then centrifuged at 3000 rpm for 5 minutes at 4°C. The serum was then aspirated with disposable pipettes, dispensed in sterile desiccation tubes, heated at 56°C for 30 minutes, and subsequently sterilized with a 0.22 μm needle filter (Catalog No. FEP204030, BIOFIL) before being collected and stored at -80°C. The study was approved by the Ethics Committee of Shandong University of Traditional Chinese Medicine (NO. 2020-10), and all methods were carried out by relevant guidelines and regulations. This study was carried out in compliance with the ARRIVE guidelines [61].

Cell grouping and intervention

Purchased human histiocytic lymphoma (U-937) cells from Shanghai Fuheng Biotechnology Co., Ltd. (Shanghai, China, Catalog No. FH0132). U-937 cells were seeded in Roswell Park Memorial Institute (RPMI) 1640 medium (Catalog No. SH30809.01, HyClone) containing 10% fetal bovine serum (FBS, TianHang Biotechnology) and 50 μg/ml gentamicin, and incubated at 37°C with 5% CO₂. To induce differentiation, U-937 cells were seeded at a density of 5×10^5 [5] cells/well in 6-well plates with a

Table 2 Details and parameter settings of molecular docking

	Protein	PDB ID	Targeting small molecules	Docking center (x,y,z)	Protein pocket size (x,y,z)	
Proteins with corresponding targeting small molecules	TLR4	3ULA	Stepharine [44]	35.5,23.2,2.0	31.9,27.5,25.1	
	NOS2	4NOS	S-ethylisothiourea [45]	-1.8,97.7,20.4	13.1,14.1,12.1	
	TGFB1	1KLC	Disitertide [46]	9.4,0.0,0.0	26.7,30.0,10.0	
	NFKB1	1NFK	Kamebakaurin [47]	0.4,-0.1,0.2	18.8,16.2,14.5	
	TP53	2XOU	J-518147 [48]	124.9101.8,44.8	12.4,15.2,17.2	
	MIF	1LJT	ISO-1 [49]	-40.9,40.4,7.5	16.7,16.7,18.8	
	SYK	3SRV	GSK143 [50]	0.0,-1.7,-27.3	19.6,16.8,17.1	
	MMP9	4XCT	N73 [51]	18.4,-17.1,19.7	15.4,20.5,18.1	
	PPARG	1FM6	Rosiglitazone maleate [52]	17.0,-21.1,11.8	19.9,20.2,16.7	
	XIAP	5M6H	AT-IAP [53]	-13.4,-18.6,-5.0	18.9,20.7,21.7	
	PTGS2	1PXX	Diclofenac [54]	27.1,24.3,14.7	15.4,16.7,16.5	
	STAT3	6NUQ	SD36 [55]	13.6,54.0,-0.1	19.8,30.6,22.0	
	TNF	2AZ5	SPD304 [56]	-19.2,74.5,33.8	19.1,18.2,18.5	
	CHRNA7	3SQ6	GTS21 [57]	2.7,4.6,-0.1	19.0,24.0,12.9	
	PIK3CG	2A4Z	AS-604850 [58]	44.0,14.3,32.0	19.4,13.9,16.5	
	IL2	1QVN	SP4206 [59]	16.8,17.7,81.4	20.2,29.2,25.9	
	MAPK14	6SFO	SR-138	0.0,1.1,-19.2	20.4,16.9,25.8	
	AKT1	3O96	Akt inhibitor VIII [60]	9.7,-7.8,10.6	17.7,25.8,22.3	
	Proteins with eutectic ligands	IL6	1ALU	NA	-7.7,-12.7,0.0	15.1,13.9,12.4
		CCR1	7VL8	NA	120.6120.7124.4	15,20.5,24.5
IL4R		3BPN	NA	12.0,8.5,42.9	16.9,15.6,12.7	
VEGFA		6ZFL	NA	22.9,19.4,2.2	13.7,15.6,15.7	
ICAM1		1MQ8	NA	-16.3,41.0,-20.9	17.9,12.2,14.4	
IFNG		6E3L	NA	-2.7,-6.9,-11.9	15.6,16.5,13.0	
IL1B		6Y8I	NA	7.5,25.5,7.1	19.8,14.2,13.8	
CXCL8		6WZM	NA	23.9,-2.1,31.3	14.3,17.0,16.4	
CXCL2		5OB5	NA	-3.2,20.1,-22.7	12.5,12.2,13.2	
Blind docking protein	CCL2	1DOK	NA	14.526,49.282,33.197	58.373,40.999,39.281	
	CXCL10	1O7Y	NA	49.12,8.793,8.502	45.099,49.176,51.687	
	STAT1	1YVL	NA	-10.34,-26.601,166.516	102.488,95.296,149.498	
	IL1A	2L5X	NA	35.574,-1.905,-0.757	37.913,47.5,35.205	
	SPP1	AF-P10451-F1	NA	-15.373,-2.209,8.391	135.821,88.635,139.822	
	IL10	2H24	NA	15.516,22.87,3.383	45.294,38.699,73.842	
	CD14	4GLP	NA	44.923,57.035,-3.18	30,30,30	

volume of 200 µl, 40 µl of 500 ng/ml phorbol 12-myristate 13-acetate (PMA, Catalog No. P6741, Solarbio) was added, and the plates were incubated for 48 hours. After twice washing the PMA-induced differentiated cells with fresh medium, the cultures were incubated for 12 hours at 37 °C with 5% CO₂. After two washes, the fresh culture medium was added and incubated for 12 hours at 37 °C with 5% CO₂. Subsequently, except for the blank group, 1 µg/ml of LPS (Catalog No. GC205009, Solarbio) was added to other groups, and the incubation period was extended to 2 hours [62]. In the model group, blank serum was administered, while 5 and 10% serum groups

received 5 and 10% concentrations of drug-containing serum (HQGWWD serum) diluent, respectively before being cultured for 24 hours.

MTT assay of the effect of drug containing serum of HQGWWD on cell viability

MTT (MTT Cell Proliferation and Cytotoxicity Assay Kit, Catalog No. C0009S, Beyotime) assay was performed to evaluate the effect of HQGWWD on cell activity. In the 96-well plate with incubated cells, RPMI 1640 medium containing 10% fetal bovine serum was added in the control group, and blank serum, 5, 10,

Table 3 The information of the active compounds in HQGZWWD

Molecule ID	Molecule Name	OB	DL	Source
MOL000033	(24S)-24-Propylcholesta-5-ene-3beta-ol	36.23	0.78	<i>Hedysarum Multijugum Maxim.</i>
MOL000073	(+)-Epicatechin	48.96	0.24	<i>Cinnamomi Ramulus</i>
MOL000096	(-)-Catechin	49.68	0.24	<i>Jujubae Fructus</i>
MOL000098	Quercetin	46.43	0.28	<i>Hedysarum Multijugum Maxim., Jujubae Fructus</i>
MOL000211	Betulinic acid	55.38	0.78	<i>Hedysarum Multijugum Maxim., Paeoniae Radix Alba, Jujubae Fructus</i>
MOL000239	Kumatakenin	50.83	0.29	<i>Hedysarum Multijugum Maxim.</i>
MOL000296	Hederagenin	36.91	0.75	<i>Hedysarum Multijugum Maxim.</i>
MOL000354	Isorhamnetin	49.6	0.31	<i>Hedysarum Multijugum Maxim.</i>
MOL000358	beta-Sitosterol	36.91	0.75	<i>Cinnamomi Ramulus, Paeoniae Radix Alba, Zingiber Officinale Roscoe, Jujubae Fructus</i>
MOL000359	3-epi-beta-Sitosterol	36.91	0.75	<i>Cinnamomi Ramulus, Paeoniae Radix Alba</i>
MOL000371	3,9,10-Trimethoxypterocarpan	53.74	0.48	<i>Hedysarum Multijugum Maxim.</i>
MOL000378	7-O-Methylisomucronulatol	74.69	0.3	<i>Hedysarum Multijugum Maxim.</i>
MOL000379	9, 10-Dimethoxypterocarpan-3-O-β-D-glucoside	36.74	0.92	<i>Hedysarum Multijugum Maxim.</i>
MOL000380	Astrapterocarpan	64.26	0.42	<i>Hedysarum Multijugum Maxim.</i>
MOL000387	Bifendate	31.1	0.67	<i>Hedysarum Multijugum Maxim.</i>
MOL000392	Formononetin	69.67	0.21	<i>Hedysarum Multijugum Maxim.</i>
MOL000398	Isoflavone	109.99	0.3	<i>Hedysarum Multijugum Maxim.</i>
MOL000417	Calycosin	47.75	0.24	<i>Hedysarum Multijugum Maxim.</i>
MOL000422	Kaempferol	41.88	0.24	<i>Hedysarum Multijugum Maxim., Paeoniae Radix Alba</i>
MOL000433	Folic acid	68.96	0.71	<i>Hedysarum Multijugum Maxim.</i>
MOL000438	(R)-Isomucronulatol	67.67	0.26	<i>Hedysarum Multijugum Maxim.</i>
MOL000439	Isomucronulatol 7,2'-di-O-glucoside	49.28	0.62	<i>Hedysarum Multijugum Maxim.</i>
MOL000442	3,4-(4-Methoxy-6-hydroxy-1,2-phenyleneoxy)-5-hydroxy-7-methoxy-2H-1-benzopyran	39.05	0.48	<i>Hedysarum Multijugum Maxim.</i>
MOL000449	Stigmasterol	43.83	0.76	<i>Zingiber Officinale Roscoe, Jujubae Fructus</i>
MOL000492	Cianidanol	54.83	0.24	<i>Cinnamomi Ramulus, Paeoniae Radix Alba, Jujubae Fructus</i>
MOL000627	(+)-Stepholidine	33.11	0.54	<i>Jujubae Fructus</i>
MOL000783	Protoporphyrin IX	30.86	0.56	<i>Jujubae Fructus</i>
MOL000787	Protopine	59.26	0.83	<i>Jujubae Fructus</i>
MOL001454	Berberine	36.86	0.78	<i>Jujubae Fructus</i>
MOL001522	Coclaurine	42.35	0.24	<i>Jujubae Fructus</i>
MOL001736	(-)-Taxifolin	60.51	0.27	<i>Cinnamomi Ramulus</i>
MOL001771	Clionasterol	36.91	0.75	<i>Zingiber Officinale Roscoe</i>
MOL001910	11alpha, 12alpha-epoxy-3beta-23-dihydroxy-30-norolean-20-en-28, 12Beta-olide	64.77	0.38	<i>Paeoniae Radix Alba</i>
MOL001919	Palbinone	43.56	0.53	<i>Paeoniae Radix Alba</i>
MOL001921	Lactiflorin	49.12	0.8	<i>Paeoniae Radix Alba</i>
MOL001924	Paeoniflorin	53.87	0.79	<i>Paeoniae Radix Alba</i>
MOL002773	beta-Carotene	37.18	0.58	<i>Jujubae Fructus</i>
MOL003410	Ziziphin_qt	66.95	0.62	<i>Jujubae Fructus</i>
MOL004350	Ruvoside_qt	36.12	0.76	<i>Jujubae Fructus</i>
MOL004576	Taxifolin	57.84	0.27	<i>Cinnamomi Ramulus</i>
MOL006129	[(3R,5R)-3-acetyloxy-1-(3,4-dimethoxyphenyl)decan-5-yl] acetate	48.73	0.32	<i>Zingiber Officinale Roscoe</i>
MOL007213	Nuciferin	34.43	0.4	<i>Jujubae Fructus</i>
MOL008034	Ceanothic acid	73.52	0.77	<i>Jujubae Fructus</i>
MOL008698	Dihydrocapsaicin	47.07	0.19	<i>Zingiber Officinale Roscoe</i>
MOL011169	Ergosterol peroxide	44.39	0.82	<i>Cinnamomi Ramulus</i>
MOL012921	Stepharine	31.55	0.33	<i>Jujubae Fructus</i>

Table 3 (continued)

Molecule ID	Molecule Name	OB	DL	Source
MOL012946	Zizyphus-Saponin I	32.69	0.62	<i>Jujubae Fructus</i>
MOL012961	Jujuboside A _{qt}	36.67	0.62	<i>Jujubae Fructus</i>
MOL012976	Coumestrol	32.49	0.34	<i>Jujubae Fructus</i>
MOL012981	Daechuine S7	44.82	0.83	<i>Jujubae Fructus</i>
MOL012986	Jujubasaponin V _{qt}	36.99	0.63	<i>Jujubae Fructus</i>
MOL012989	Jujuboside C _{qt}	40.26	0.62	<i>Jujubae Fructus</i>
MOL012992	Mauritine D	89.13	0.45	<i>Jujubae Fructus</i>
MOL013357	Stigmast-4-ene-3,6-diol	34.37	0.78	<i>Jujubae Fructus</i>

20, and 40% drug-containing serum were added in the HQGZWWDD drug-containing serum group. Incubate at 37 °C and 5% CO₂ for 24h, then add MTT 10 μL/well, continue incubating for 4h, add 100 μL/well of Formazan solution, and determine the absorbance by 570 nm 4 h later.

ELISAs

Interleukin-1 beta (IL-1β), IL-6, IL-10, and TGF-β1 were detected in the culture supernatant using the following Elisa Kit: Human IL-1β (Interleukin 1 Beta) ELISA Kit (Catalog No. E-EL-H0149c, Elabscience), Human IL-6 (Interleukin 6) Elisa Kit (Catalog No. E-EL-H6156, Elabscience), Human IL-10 (Interleukin 10) Elisa Kit (Catalog No. E-EL-H6154, Elabscience), and TGF-β1 (Transforming Growth Factor Beta 1) ELISA Kit (Catalog No. E-EL-0162c, Elabscience). All steps conform to the manufacturer's guidelines.

Quantitative real-time PCR

For further confirmation of HQGZWWDD's role in macrophage polarization regulation, qRT-qPCR was used to detect the levels of expression of α7 nicotinic acetylcholine receptor (α7 nAChR), M1 macrophage marker genes CD11 antigen-like family member C (CD11c), Nitric Oxide Synthase 2 (NOS2), M2 macrophage marker genes Arginase-1 (Arg1), and Mannose Receptor C-Type 1 (CD206).

The cells' total RNA was extracted using the TRIzol method (Catalog No. R401-01, Vazyme) and reverse transcribed via a reverse transcription kit (Catalog No. R223-01, Vazyme) by the manufacturer's instructions at 50 °C for 15 minutes, followed by reverse transcription at 85 °C for 5 seconds. Gene expression levels were detected using LightCycleer 480 SYBR Premix Ex Taq II (Roche, Germany). GAPDH was used as an internal reference and its expression was used to normalize the data. Quantitative relationships were analyzed utilizing the 2-CT method.

The following primer sequence was designed by Accurate Biotechnology Co., Ltd.: CD11c: 5'-TCATCACTG ATGGGAGAAAACA-3'/5'-CCCAATTGCATAAC GAATGAT-3'; NOS2: 5'-GTTCTCAGCCCAACAATA CAAGA-3'/5'-GTGGACGGGTCGATGTCAC-3'; Arg1: 5'-AGACAGCAGAGGAGGTGAAGAGTAC-3'/5'-AAG GTAGTCAGTCCCTGGCTTATGG-3'; CD206: 5'-CTC TGTTTCAGCTATTGGACGC-3'/5'-CGGAATTTCTGG GATTCAGCTTC-3'; α7 nAChR: 5'-TCTGACTGTCTT CATGCTGCTTGTG-3'/5'-TCACTGTCACGACCA CTGAGAGG-3'; GAPDH: 5'-AAATCCCATCACCAT CTCCAG-3'/5'-TGATGACCCTTTTGGCTCCC-3'.

Western blot analysis


The protein expression level of α7 nAChR is evaluated using Western blot. To extract protein, add the appropriate amount of radioimmunoprecipitation assay lysis (RIPA, Catalog No. G2002-100 ml, Servicebio) and phenylmethylsulfonyl fluoride (PMSF, Catalog No. ST506-2, Beyotime). Using the Enhanced BCA Protein Assay Kit (Beyotime Biotechnology, China), protein concentration could be determined. Using SDS-PAGE electrophoresis, proteins were separated and transferred to a PVDF membrane. The membranes were placed in 5% skim milk powder dissolved in TBST, incubated at room temperature for 60 minutes, and conjugated to primary antibodies against α7 nAChR (Catalog No. ab216485, abcam, 1:500) and (Catalog No. ab181602, abcam, 1:5000) overnight at 4 °C. The membrane was washed five times in TBST and then combined for 1 hour at room temperature with goat anti-rabbit IgG (Catalog No. SA00001-2, Proteintech, 1:5000). Using FluorChem Q3.4, the optical density intensity of each band was measured (ProteinSimple, USA).

Immunofluorescence


After fixing cells in 4% paraformaldehyde for 20 minutes (Cat. No. P0099-100 ml, Beyotime), they were incubated in TritonX-100 (Catalog No. P0099-100 ml, Beyotime) for 10 minutes at room temperature and

then closed in 5% BSA (Catalog No. ST025-5g, Beyotime). The samples were then conjugated with anti-CD68 antibodies (Catalog No. ab955, abcam, 1:200), anti-CD86 antibodies (Catalog No. 13395-1-AP, Proteintech, 1:200), and anti-CD206 antibodies (Catalog No. 18704-1-AP, Proteintech, 1:200) and left overnight at 4°C. Incubate for 1 hour at room temperature with


anti-rabbit or anti-mouse IgG. Label the nuclei with DAPI Staining Solution (Catalog No. C1005, Beyotime), then seal the slices with Antifade Mounting Medium (Catalog No. P0126-25 ml, Beyotime) and photographed using fluorescence microscopy (Nikon, Japan).



(a)



(b)



(c)

Fig. 2 Acquisition of overlapping targets and PPI Analysis. **a** The Venn diagram shows 34 overlapping targets between HQGZWWD active compounds, macrophage polarization and inflammation. **b** Expression of 34 overlapping targets in M1/M2 macrophages. **c** The network diagram shows the PPI network of 36 overlapping targets. The color depth is related to the MCC score. The redder the color, the higher the MCC score

Statistical analysis

The SPSS 26 statistical program (SPSS, USA) was used to analyze the data. A t-test using independent samples was used in order to compare the normal group and the model group. To compare the model group with each treatment group, one-way ANOVA was used under the conditions of normality and homogeneity of variance, as well as the LSD-t test for multiple comparisons. $P < 0.05$ was considered to be statistically significant.

Results

Screening of active ingredients and prediction of targets

Under the conditions of $OB \geq 30\%$ and $DL \geq 0.18$, 54 active ingredients in HQGZWWDD were identified (Table 3). In addition, 859 targets were extracted from the databases of TCMSP and SwissTargetPrediction (supplementary file 1).

Target screening of Huangqi Guizhi Wuwu decoction in regulating macrophage polarization and inflammation

The GeneCards database identified 9972 targets related to macrophage polarization and 11,109 targets related to inflammation. AS-IV, the active component of HQ, was

found to exert anti-inflammatory effects by activating $\alpha 7$ nAChR in a previous study [27], and numerous studies have demonstrated that $\alpha 7$ nAChR promotes M1 macrophage polarization and therefore inhibits inflammation [63–65]. Target analysis of HQGZWWDD revealed that $\alpha 7$ nAChR is a target for the active ingredients of HQ, GZ, BS, DZ, and SJ. In the GeneCards database, $\alpha 7$ nAChR was also associated with macrophage polarization and inflammation (supplementary file 2). A combination of previous studies and literature research was conducted, which shows that $\alpha 7$ nAChR with the top 200 results in GeneCards was used as the primary target for macrophage polarization and inflammation. Following that, the targets of HQGZWWDD were mapped to them, and a Venn diagram (Fig. 2a) was created, yielding 34 common targets and 51 related active substances. As shown in Fig. 2b, there are some differences in the expression of 34 intersection targets in M1 and M2 macrophages, indicating that these targets may be related to macrophage polarization and inflammation.

Construction of PPI network

The network was then imported into Cytoscape 3.8.1. The targets were scored using the MCC algorithm in the





Fig. 3 Results of Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. **a** Top 6 significantly enriched terms in BP, CC and MF. **b** Display of pathways related to macrophage polarization in KEGG enrichment analysis

cytoHubba plugin, and the network was plotted (Fig. 2c). As depicted in Fig. 2c, PPI network targets such as IL1B, IL10, IL6, TNF, and STAT3 may play crucial roles.

Enrichment analysis results of the GO and KEGG databases

With a threshold of $P < 0.05$, the Go enrichment analysis yielded 1917 entries, including 1674 biological processes (BP), 9 cellular components (CC), and 36 molecular

functions (MF). As depicted in Fig. 3a, BP is primarily comprised of cellular response to biotic stimulus, cellular response to lipopolysaccharide, cellular response to a molecule of bacterial origin, and macrophage activation. According to the CC analysis, it is primarily associated with the external side of the plasma membrane, the secret granular lumen, and the cytoplasmic vesicle lumen. The MF consists of the following components: cytokine receptor binding, cytokine activity, receiver



ligand activity, and signaling receiver activator activity. As depicted in Fig. 3b, KEGG enrichment analysis revealed that several pathways associated with macrophage polarization were significantly enriched. These pathways were primarily associated with the TGF-beta signaling pathway, NF-kappa B signaling pathway, JAK-STAT signaling pathway, TNF signaling pathway, PI3K-Akt signaling pathway, Rheumatoid arthritis, and Inflammatory bowel disease.

Construction of C-T-P network

A C-T-P network was constructed to clarify the relationship between active compounds, targets, and pathways

in HQGZWW (Fig. 4). Important flavonoids in HQGZWW, such as quercetin, were observed to act on IL1B, IL10, and PPARG, while kaempferol could act on NOS2, PTGS2, and PPARG. Moreover, isorhamnetin can act on PPARG, NOS2, and MMP9, and beta-sitosterol can act on CHRNA7 and PTGS2. This indicates that the active ingredients in HQGZWW have a synergistic effect on multiple targets.

Molecular docking results

The docking of 34 targets with 51 active compounds of HQGZWW was conducted. The docking score is illustrated in Fig. 5. In general, it is believed that when the binding energy is less than zero, the compound and




Fig. 5 Heat maps of the docking scores for overlapping targets combined with active compounds

protein may bind spontaneously and that the lower the binding energy, the higher the likelihood of interaction [66]. In the docking results, most of the binding complexes have high binding affinity and the average binding energy is -6.28 kcal/mol. The binding energy of 79.76% is less than -5.0 kcal/mol and 37.77% of the binding energy of mol is less than -7.0 kcal/mol. In addition, the average binding energy of the key compounds quercetin, kaempferol, isorhamnetin, and beta sterol to the target protein is less than -5 kcal/mol, suggesting that they have a good binding ability to the target protein. It can be seen that most of the active components in HQGZWWD have a certain binding activity to the protein target. 18 proteins have corresponding targeted small molecular drugs, and the scores of targeted small molecules and target proteins are shown in Table 4. Compared with the docking scores of key compounds and target proteins of HQGZWWD, it was found that the binding energy of key compounds of HQGZWWD with some target proteins was better than that of targeted small molecules (Table 5). Comparing the binding energy and amino acid sites between the active components of HQGZWWD and positive drugs, it was found that quercetin, isorhamnetin, and kaempferol had the better binding ability with $\alpha 7$ nachr, TP53, and MMP9 (Fig. 6). For example, the binding energy of quercetin with positive drug GTS-21 of $\alpha 7$ nachr was equal, and they all formed a hydrogen bond with ASN15 (A). The binding energy of isorhamnetin to GTS-21 is also equal, but isorhamnetin connects to TYR62 (A),

PHE2 (A), and ARG4 (A) through three hydrogen bonds. The binding energy of kaempferol is better than that of GTS-21. It connects with ASN15 (A) and TYR62 (A) through two hydrogen bonds.

Cell viability assays

Cell activity assay was performed to evaluate the possible cytotoxicity of HQGZWWD. As shown in Fig. 7, blank serum, 5 and 10% HQGZWWD drug-containing serum had no significant effect on cell activity, while 20 and 40% HQGZWWD drug-containing serum decreased cell activity ($P < 0.01$, Figs. 7). Therefore, we selected 5 and 10% of the drug-containing serum concentration for further experiments.

HQGZWWT serum can promote the polarization of M2 macrophages

NOS2 and CD11C are markers of M1 macrophages, while Arg1 and CD206 are markers of M2 macrophages. As shown in Fig. 8, after LPS stimulation, the expression of M1 macrophage markers NOS2 and CD11c in the model group increased ($P < 0.05$, Fig. 8a and b) while the expression of M2 macrophage markers Arg1 and CD206 decreased ($P < 0.05$, Fig. 8c and d), which indicated that LPS stimulation induced the conversion of U-937 macrophages into M1 macrophages. Compared to the control group, HQGZWWD serum was able to effectively promote the transformation of macrophage M1 to M2, decrease the expression level of NOS2 and CD11c, and increase the expression level of Arg1 and CD206, with the 10% drug-containing serum group having the greatest effect ($P < 0.05$, Fig. 8).

The results of the double immunofluorescence assay were comparable. Expression of $CD68^+CD86^+$ and $CD68^+CD206^+$ was used to identify and evaluate M1 and M2 macrophages, respectively (Fig. 9). Stimulation with LPS may increase the number of $CD68^+CD86^+$ double-positive macrophages (M1 macrophages) ($P < 0.01$, Fig. 9b). ($P < 0.05$ and $P < 0.01$, respectively, Fig. 9b). An intervention containing 10% of a drug-containing serum may increase the number of $CD68^+CD206^+$ double-positive macrophages (M2 macrophages) ($P < 0.01$, Fig. 9c). These findings suggest that HQGZWWD serum can increase the number of M2 macrophages, decrease the number of M1 macrophages, and facilitate the transformation of M1 macrophages into M2 macrophages.

HQGZWWT serum can inhibit inflammatory response induced by LPS

After stimulation with LPS, U-937 cells were transformed into M1 macrophages. In Fig. 10, LPS stimulation increased the pro-inflammatory factors IL-1 β and IL-6 secreted by M1 macrophages and decreased the

Table 4 Molecular docking score for targeting small molecules

Target	Positive Controls	Binding Energy (kcal/mol)
TLR4	Stepharine	-2.7
NOS2	S-ethylisothiourea	-3.8
TGFB1	Disitertide	-4.9
NFKB1	Kamebakaurin	-5.7
TP53	J-518147	-5.9
MIF	ISO-1	-7.7
SYK	GSK143	-8
MMP9	N73	-8.4
PPARG	Rosiglitazone maleate	-8.8
XIAP	AT-IAP	-8.9
PTGS2	Diclofenac	-9.1
STAT3	SD36	-9.1
TNF	SPD304	-9.3
CHRNA7	GTS21	-6.8
PIK3CG	AS-604850	-9.9
IL2	SP4206	-11.3
MAPK14	SR-138	-11.5
AKT1	Akt inhibitor VIII	-14.9

Table 5 Details of docking results of key compounds in HQGZWWDD

Target	Small molecule	Num. H-bonds	Amino acid residue	Binding Energy (kcal/mol)
TP53	Quercetin	2	LEU'145	-7.5
	Isorhamnetin	4	LEU'145/GLU'221/ASP'228	-7.5
	Kaempferol	3	LEU'145/GLU'221/PRO'152	-7.4
	J-518147 (positive controls)	1	LEU'145	-5.9
TGFB1	Quercetin	3	TYR'39/ALA'41/ASN'103	-6.4
	Isorhamnetin	1	CYS'78	-6.2
	Beta-sitosterol	NA	NA	-6.4
	Kaempferol	3	CYS'44/ILE'105/ASN'103	-6.3
	Disitertide (positive controls)	3	CYS'44/GLN'19/TYR'21	-4.9
CHRNA7	Quercetin	1	ASN'15	-6.8
	Isorhamnetin	3	TYR'62/PHE'2/ARG'4	-6.8
	Kaempferol	2	ASN'15/TYR'62	-7.2
	GTS21 (positive controls)	1	ASN'15	-6.8
SYK	Quercetin	6	GLU'452/ALA'451/SER'511/ASP'512	-8.1
	GSK143 (positive controls)	5	GLU'452/ALA'451/SER'511	-8.0
TLR4	Quercetin	4	ARG'274/ILE'299/ASP'270/CYS'301	-7.2
	Isorhamnetin	2	CYS'301/ARG'274	-7.7
	Beta-sitosterol	1	ASP'247	-8.1
	Kaempferol	2	ASP'247/ARG'274	-7.0
	Stepharine (positive controls)	3	CYS'264/SER'298/LYS'294	-2.7
	NOS2	Quercetin	1	MET'355
Isorhamnetin		NA	NA	-8.1
Beta-sitosterol		NA	NA	-9.0
Kaempferol		1	GLU'377	-8.8
S-ethylisothiourea (positive controls)		2	TYR'373/TYR'374	-3.8
MMP9	Quercetin	3	ALA'189/GLU'227	-11.3
	Isorhamnetin	3	ALA'189/TYR'248/LEU'188	-10.1
	Beta-sitosterol	NA	NA	-8.4
	Kaempferol	3	ALA'189/LEU'188	-10.1
	N73 (positive controls)	1	ALA'189	-8.4

anti-inflammatory factors IL-10 and TGF- β 1 secreted by M2 macrophages ($P < 0.05$). HQGZWWDD serum was able to reduce the level of inflammation, exert an anti-inflammatory effect, reduce the secretion of IL-1 β and IL-6, and increase the secretion of IL-10 and TGF- β 1, with the 10% drug-containing serum group having the greatest effect ($P < 0.05$).

HQGZWWDD serum can up-regulate the expression level of α 7 nAChR

In a previous study, we discovered that AS-IV can regulate inflammation by increasing α 7 nAChR

expression. Through molecular docking, we found that α 7 nAChR has an excellent ability to bind to the active components of HQGZWWDD. To confirm the effect of HQGZWWDD on α 7 nAChR, qRT-PCR and WB were used to determine its transcriptional level and protein expression level. It was found that the transcriptional level and protein expression level of α 7 nAChR declined following LPS stimulation ($P < 0.01$, Fig. 11a and c), and that HQGZWWDD serum could partially restore these levels (Fig. 11), with 10% drug-containing serum having the greatest effect ($P < 0.05$ or $P < 0.01$, Fig. 11a and c).




Fig. 6 Display of docking results between quercetin, isorhamnetin, kaempferol and CHRNA7, tp53, MMP9

Discussion

Inflammation is crucial for maintaining human homeostasis. In the event of an infection, macrophages activate and differentiate into M1 macrophages, secrete inflammatory factors, promote inflammation, and eliminate pathogens. M2 macrophages promote tissue repair and wound healing and play a crucial role in the regression of inflammation. The cholinergic anti-inflammatory pathway plays a crucial role in macrophage phenotypic transformation. It can inhibit M1 macrophage polarization while promoting M2 macrophage polarization. The cholinergic anti-inflammatory pathway plays a key

role in the phenotypic transformation of macrophages by inhibiting M1 macrophage polarization and promoting M2 macrophage polarization, thereby exerting anti-inflammatory effects [64, 67, 68]. Previous research has demonstrated that AS-IV can increase the expression of $\alpha 7$ nAChR and inhibit inflammation [27]. GZ and BS are capable of increasing cholinergic nerve activity and regulating immune inflammatory response [69]. This provides a foundation for further investigation into the mechanism by which HQGZWWD regulates macrophage polarization and anti-inflammation. From the perspective of network pharmacology, the potential




Fig. 7 Effect of HQGZWWDD drug-containing serum on cell activity

mechanism of HQGZWWDD was elucidated as inhibiting inflammation by regulating macrophage polarization. It has been demonstrated that HQGZWWDD can concentration-dependently up-regulate the expression of $\alpha 7$ nAChR, inhibit the polarization of M1 macrophages induced by LPS, promote the polarization of M2 macrophages, reduce the level of inflammation, and exert an anti-inflammatory effect.

This study screened 54 active components and 859 targets of HQGZWWDD. After mapping them with macrophage polarization and inflammation targets, 51 active components and 34 targets of HQGZWWDD that may regulate macrophage polarization were screened. After mapping them with targets associated with macrophage polarization and inflammation, 51 active components and 34 targets that may regulate macrophage polarization and inflammation were chosen. After constructing the PPI network, 34 intersection targets were scored by MCC, with IL1B, IL6, and IL10 having the highest MCC scores. M1 macrophages secrete pro-inflammatory factors, including IL-1 β and IL-6. Despite having a low score in the PPI network, it (TGF- β 1) and IL-10 are not only anti-inflammatory factors secreted by M2 macrophages but also play an important role in promoting M2 polarization of macrophages [70, 71]. As demonstrated by our experimental findings, HQGZWWDD serum inhibits the secretion of IL-1 β and IL-6 and increases the secretion of IL-10 and TGF- β 1 to exert an anti-inflammatory effect.

According to the PPI network, AKT1, PTGS2, PPARG, and MIF may also be involved in the regulation of macrophage polarization and inflammation by HQGZWWDD. For instance, AKT1 can promote the polarization of M2 macrophages, and AKT1 deficiency can result in the overexpression of the M1 phenotype in macrophages [72]. PGE2, a metabolite of PTGS2, can enhance the IL4R signal and enhance M2 macrophage activation [73]. By increasing H3K36me2 levels on the PPARG site, STAT6 levels can be up-regulated, thereby promoting macrophage M2 polarization [74]. Overexpression of MMP9 promotes the M1 phenotype transformation induced by LPS in mouse lung macrophages, whereas inhibition of MMP9 expression promotes the M2 phenotype transformation [75]. Multiple targets appear to be involved in the regulation of macrophage polarization and inflammatory response by HQGZWWDD, as suggested by these results.

Multiple pathways related to macrophage polarization and inflammation were enriched in the KEGG pathway enrichment analysis, including the JAK/STAT signaling pathway, PI3K/Akt signaling pathway, MAPK signaling pathway, NF-kappa B (NF- κ B) signaling pathway, Toll-like receptor signaling (TLRs) pathway, TNF signaling pathway, and TGF beta signaling pathway. The activation of the JAK/STAT pathway plays a crucial role in the polarization of macrophages. HQGZWWDD may primarily affect JAK/STAT1 or JAK/STAT3 pathway, with the activation of the JAK/STAT1 pathway increasing CXCL10 secretion and promoting M1 polarization of macrophages [76] and activation of JAK/STAT3 pathway inducing M2 polarization of macrophages [77]. By regulating the expression of apoptosis-related proteins to promote the polarization of M2 macrophages, the PI3K/AKT pathway plays an anti-inflammatory role [78]. The NF- κ B signal pathway and the MAPK signal pathway are closely related. MAPK can activate the transcription factor NF- κ B/AP-1 and promote M1 polarization [79]. $\alpha 7$ nAChR can regulate the JAK/STAT3, NF- κ B, and MAPK signaling pathways in the aforementioned channels [80–82]. Molecular docking also demonstrated that the pharmaceutical components of HQGZWWDD had a strong binding affinity with $\alpha 7$ nAChR and that the activation of $\alpha 7$ nAChR could promote the polarization of M2 macrophages, reduce the secretion of pro-inflammatory cytokines IL-1 β and IL-6, and increase the secretion of anti-inflammatory cytokines IL-10 and TGF- β 1 [83]. Previous research conducted by our group demonstrated that AS-IV can upregulate $\alpha 7$ nAChR, inhibit the IKK β /NF- κ B pathway, reduce the expression of IL-1 β and TNF- α , and inhibit the inflammatory response [27]. In this study, using network pharmacology, it was discovered that the active components of HQGZWWDD can regulate




Fig. 8 Effect of Huangqi Guizhi Wuwu decoction (HQGZWWD) on marker genes of M1 and M2 macrophages. (a-d) qRT-PCR for the relative mRNA expression levels of M1 macrophage marker gene NOS2, CD11c and M2 macrophage marker gene Arg1 and CD206 IL-10 and TGF- β 1. The data are presented as the means \pm SD, $n=3$. * $P < 0.05$ vs. the control group. $\Delta P < 0.05$, $\Delta\Delta P < 0.01$ vs. LPS + Blank serum group. $\blacktriangle P < 0.05$ vs. LPS + 10% serum group

multiple downstream pathways of $\alpha 7$ nAChR. Our experimental results confirm that HQGZWWD serum can increase the expression of $\alpha 7$ nAChR and reduce inflammation, which is consistent with previous research.

Moreover, in the KEGG pathway enrichment analysis, we enriched a number of disease-related pathways, including Rheumatoid arthritis, Lipid and atherosclerosis, Insulin resistance, Asthma, and Alzheimer disease. According to numerous studies [84–88], the progression of these diseases is closely associated with macrophage polarization. According to studies, HQGZWWD may

improve rheumatoid arthritis and atherosclerosis by improving the level of inflammation [89–91], but it remains to be determined whether it can exert an anti-inflammatory effect by regulating macrophage polarization. Currently, there is no research on HQGZWWD in the treatment of insulin resistance, asthma, or Alzheimer's disease. However, the results of this network pharmacological study suggest that HQGZWWD may play a role in the progression of the aforementioned diseases by regulating macrophage polarization. Despite its




Fig. 9 Effect of Huangqi Guizhi Wuwu decoction (HQGZWW) on M1 and M2 macrophages. **a** Representative images of CD68 + CD86 + macrophages (magnification power: 400×). **b** Statistics of the number of CD68 + CD86 + macrophages. **c** Representative images of CD68 + CD206 + (magnification power: 400×). **d** Statistics of the number of CD68 + CD206 + macrophages. The data are presented as the means ± SD, n = 3. *P < 0.05, **P < 0.01 vs. the control group. ΔΔP < 0.01 vs. LPS + Blank serum group. ▲▲P < 0.01 vs. LPS + 10% serum group. ○P < 0.05 vs. LPS + 5% serum group

therapeutic potential, further research is needed in order to determine its specific mechanism.

Quercetin, isorhamnetin, kaempferol, and beta-sitosterol have high degree values in the C-T-P network, and the results of molecular docking indicate that these

four key compounds have strong binding ability. All of them had significant anti-inflammatory activity [92–95]. Quercetin and kaempferol can inhibit the polarization of M1 macrophages [96, 97], whereas isorhamnetin can reduce oxidative stress, regulate the polarization of M2




Fig. 10 Regulatory effect of Huangqi Guizhi Wuwu decoction (HQGZWWD) on inflammatory cytokines. **a–d** ELISA for the expression of the pro-inflammatory cytokines IL-1 β , IL-6 and the anti-inflammatory cytokines IL-10 and TGF- β 1. The data are presented as the means \pm SD, n = 3. *P < 0.05, **P < 0.01 vs. the control group. Δ P < 0.05, $\Delta\Delta$ P < 0.01 vs. LPS + Blank serum group. $\blacktriangle\blacktriangle$ P < 0.01 vs. LPS + 10% serum group

macrophages, and promote the functional recovery of rats with spinal cord injury [98]. β -sitosterol can inhibit M1 macrophage polarization, enhance M2 macrophage polarization, and reduce inflammation in mice with rheumatoid arthritis [99]. In addition, molecular docking results suggest that Quercetin, isorhamnetin, and kaempferol have higher docking scores, more hydrogen bonds, and better binding ability with α 7 nacr, TP53, and MMP9 than positive drugs. Our experimental results show that HQGZWWD can regulate the

expression level of α 7 nacr, which is consistent with molecular docking results.

Conclusion

According to the results of network pharmacology in this study, several effective compounds in HQGZWWD can regulate macrophage polarization and inflammation via multiple targets and pathways. As a result of the results, HQGZWWD serum could




Fig. 11 Huangqi Guizhi Wuwu decoction (HQGZWW) regulates $\alpha 7$ nAChR transcription and protein level. **a** qRT-PCR for the relative mRNA expression of $\alpha 7$ nAChR. **b** Representative Western blot of $\alpha 7$ nAChR, full-length blots are presented in Supplementary Fig. 1. **c** $\alpha 7$ nAChR expression relative to the GAPDH level. ** P < 0.01 vs. the control group. $\Delta\Delta P$ < 0.01 vs. LPS + Blank serum group

up-regulate the level of $\alpha 7$ nAChR, reduce the expression of M1 macrophage marker genes NOS2 and Cd11c, inhibit the production of pro-inflammatory factors IL-1 β and IL-6, increase the expression of M2 macrophage marker genes Arg1 and CD206 and the secretion of anti-inflammatory factors IL-10 and TGF- β 1, inhibit the polarization of M1 macrophages induced by LPS, and promote the polarization of M2 macrophages to inhibit inflammation.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12906-022-03826-4>.

Additional file 1. Supplementary Fig. 1: Raw data of western blot results in Fig. 11

Acknowledgements

Thanks to everyone who contributed to this article.

Copyright permission of KEGG

We have contacted Kanehisa Laboratories. We do not directly use these KEGG Pathway map "images" in the article, we need not obtain copyright permission of KEGG. However, they believe that we have written our article using their data, they kindly ask us to cite the following articles in it [38–40].

Authors' contributions

ST W and P J conceived and designed the study; ST W, YW Q and XH W searched the related articles; ST W, WT W and MJ L performed the experiment, ST W, TS J and L W analyzed the data; ST W, TS J and L W wrote the manuscript, P J and X L revised the manuscript, P J and YC W supervised the whole process. All authors read and approved the final manuscript.

Funding

Grants supported this study from the National Natural Science Foundation of China (No. 81874449), Postdoctoral Science Foundation of China (No. 2021 M702043) and Natural Science Foundation of Shandong Province (Youth Program)(Nos. ZR2020QH307 and ZR2020QH319).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Declarations**Ethics approval and consent to participate**

The study was approved by Ethics Committee of Shandong University of Traditional Chinese Medicine (NO. 2020–10), all methods were carried out in accordance with relevant guidelines and regulations. This study was carried out in compliance with the ARRIVE guidelines. Plant accordance general statement: Experimental research and field studies on plants including the collection of plant material are comply with relevant guidelines and regulation.

Consent for publication

Not applicable.

Competing interests

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Author details

¹Shandong University of Traditional Chinese Medicine, Jinan 250014, Shandong, China. ²National Clinical Research Center for Cardiovascular Diseases of Traditional Chinese Medicine, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, China. ³Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250011, China.

Received: 23 August 2022 Accepted: 22 December 2022

Published online: 09 January 2023

References

- Medeiros AI, Serezani CH, Lee SP, Peters-Golden M. Efferocytosis impairs pulmonary macrophage and lung antibacterial function via PGE2/EP2 signaling. *J Exp Med*. 2009;206(1):61–8. <https://doi.org/10.1084/jem.20082058>.
- Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. *Biochem Pharmacol*. 2020;180:114147. <https://doi.org/10.1016/j.bcp.2020.114147>.
- Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of glucocorticoids. *Expert Opin Drug Saf*. 2016;15(4):457–65. <https://doi.org/10.1517/14740338.2016.1140743>.
- Msheik Z, El Massry M, Rovini A, Billet F, Desmouliere A. The macrophage: a key player in the pathophysiology of peripheral neuropathies. *J Neuroinflammation*. 2022;19:97. <https://doi.org/10.1186/s12974-022-02454-6>.
- Zhang Y, Li X, Luo Z, et al. ECM1 is an essential factor for the determination of M1 macrophage polarization in IBD in response to LPS stimulation. *Proc Natl Acad Sci U S A*. 2020;117(6):3083–92. <https://doi.org/10.1073/pnas.1912774117>.
- Shapouri-Moghaddam A, Mohammadian S, Vazini H, et al. Macrophage plasticity, polarization, and function in health and disease. *J Cell Physiol*. 2018;233(9):6425–40. <https://doi.org/10.1002/jcp.26429>.
- Schultze JL, Schmidt SV. Molecular features of macrophage activation. *Semin Immunol*. 2015;27(6):416–23. <https://doi.org/10.1016/j.smim.2016.03.009>.
- Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. *Nat Rev Immunol*. 2011;11(11):723–37. <https://doi.org/10.1038/nri3073>.
- Muñoz J, Akhavan NS, Mullins AP, Arjmandi BH. Macrophage polarization and osteoporosis: A review. *Nutrients*. 2020;12(10):E2999. <https://doi.org/10.3390/nu12102999>.
- Li Y, Juan CH, Chang HJ, Qin WX. Clinical study of Jiawei Huangqi Guizhi Wuwu decoction in preventing and treating peripheral neuro-sensory toxicity caused by oxaliplatin. *Chin J Integr Med*. 2006;12(1):19–23. <https://doi.org/10.1007/BF02857424>.
- Weiru X, Mingwei Y, Qi F. Retrospective study on modified Huangqi Guizhi Wuwu decoction in treating Oxaliplatin-induced peripheral neuropathy [in Chinese]. *Journal of Guangzhou University of Traditional Chinese Medicine*. 2022;39(1):24–30. <https://doi.org/10.13359/j.cnki.gzxbtcm.2022.01.005>.
- Jingyi Z, Guobing S, Bo X, Wei Z. Meta-analysis of randomized comparative study on Huangqi Guizhi Wuwu Tang in the treatment of diabetic peripheral neuropathy. *J Shenyang Pharm Univ*. 2014;31(8). <https://doi.org/10.14066/j.cnki.cn21-1349/r.2014.08.011>.
- Min T, Yunfei S, Xin L. Meta-analysis of clinical efficacy and safety of Huangqi Guizhi Wuwu decoction combined with chemical drugs in the treatment of rheumatoid arthritis [in Chinese]. *Chinese Journal of Immunology*. 2021;37(16):1964–6. <https://doi.org/10.3969/j.issn.1000-484X.2021.16.009>.
- Guangxun Y, Min C, Wencheng S, Lijun Y, Xiao F. Observation of effect of Huangqi Guizhi Wuwu decoction on rheumatoid arthritis [in Chinese]. *Chinese Journal of Clinical Healthcare*. 2019;22(4):549–52. <https://doi.org/10.3969/J.issn.1672-6790.2019.04.031>.
- Chen P, Piao X, Bonaldo P. Role of macrophages in Wallerian degeneration and axonal regeneration after peripheral nerve injury. *Acta Neuropathol*. 2015;130(5):605–18. <https://doi.org/10.1007/s00401-015-1482-4>.
- Fukui S, Iwamoto N, Takatani A, et al. M1 and M2 monocytes in rheumatoid arthritis: A contribution of imbalance of M1/M2 monocytes to Osteoclastogenesis. *Front Immunol*. 2018;8:1958. <https://doi.org/10.3389/fimmu.2017.01958>.
- Huang TC, Wu HL, Chen SH, Wang YT, Wu CC. Thrombomodulin facilitates peripheral nerve regeneration through regulating M1/M2 switching. *J Neuroinflammation*. 2020;17(1):240. <https://doi.org/10.1186/s12974-020-01897-z>.
- Zhou F, Mei J, Han X, et al. Kinsenoside attenuates osteoarthritis by repolarizing macrophages through inactivating NF-κB/MAPK signaling and protecting chondrocytes. *Acta Pharm Sin B*. 2019;9(5):973–85. <https://doi.org/10.1016/j.apsb.2019.01.015>.
- Zhou X, Huang D, Wang R, et al. Targeted therapy of rheumatoid arthritis via macrophage repolarization. *Drug Deliv*. 2021;28(1):2447–59. <https://doi.org/10.1080/10717544.2021.2000679>.
- Yang Y, Guo L, Wang Z, et al. Targeted silver nanoparticles for rheumatoid arthritis therapy via macrophage apoptosis and re-polarization. *Biomaterials*. 2021;264:120390. <https://doi.org/10.1016/j.biomaterials.2020.120390>.
- Li M, Li Z, Ma X, et al. Huangqi Guizhi Wuwu decoction can prevent and treat oxaliplatin-induced neuropathic pain by TNFα/IL-1β/IL-6/MAPK/NF-κB pathway. *Aging (Albany NY)*. 2022;14(12):5013–22. <https://doi.org/10.18632/aging.203794>.
- Jiawei L, Yonghui W, Yanyan L, Yonggang Z, Le Z, Ruonan Z. Effect of Huangqi Guizhi Wuwu decoction on joint synovial cell apoptosis in CIA rat models [in Chinese]. *Chin J Exp Tradit Med Formulae*. 2017;23(14):171–6. <https://doi.org/10.13422/j.cnki.syfjx.2017140171>.
- Li Z, Ma D, Wang Y, et al. Astragal Radix-Coptis Rhizoma herb pair attenuates atherosclerosis in ApoE^{-/-} mice by regulating the M1/M2 and Th1/Th2 immune balance and activating the STAT6 signaling pathway. *Evid Based Complement Alternat Med*. 2022;2022:7421265. <https://doi.org/10.1155/2022/7421265>.
- Tian L, Zhao JL, Kang JQ, et al. Astragaloside IV alleviates the experimental DSS-induced colitis by remodeling macrophage polarization through STAT signaling. *Front Immunol*. 2021;12:740565. <https://doi.org/10.3389/fimmu.2021.740565>.
- Li L, Gan H, Jin H, et al. Astragaloside IV promotes microglia/macrophages M2 polarization and enhances neurogenesis and angiogenesis through PPARγ pathway after cerebral ischemia/reperfusion injury in rats. *Int Immunopharmacol*. 2021;92:107335. <https://doi.org/10.1016/j.intimp.2020.107335>.
- Liang CL, Jiang H, Feng W, et al. Total glucosides of Paeony ameliorate Pristane-induced lupus nephritis by inducing PD-1 ligands+ macrophages via activating IL-4/STAT6/PD-L2 signaling. *Front Immunol*. 2021;12:683249. <https://doi.org/10.3389/fimmu.2021.683249>.
- Jiang P, Ma D, Wang X, et al. Astragaloside IV prevents obesity-associated hypertension by improving pro-inflammatory reaction and leptin resistance. *Mol Cells*. 2018;41(3):244–55. <https://doi.org/10.14348/molcells.2018.2156>.

28. Chen J, Zhang Y, Wang Y, et al. Potential mechanisms of Guizhi decoction against hypertension based on network pharmacology and Dahl salt-sensitive rat model. *Chin Med*. 2021;16(1):34. <https://doi.org/10.1186/s13020-021-00446-x>.
29. Jiye C, Guofeng Z, Yongcheng W, et al. Effect of Guizhitang with different proportions of Cinnamomi Ramulus and Paeoniae Alba Radix in regulating TGF- β 1/Smads signaling pathway and chronic inflammation and alleviating myocardial fibrosis in salt-sensitive hypertensive rats [in Chinese]. *Chin J Exp Tradit Med Formulae*. 2020;26(1):50–8. <https://doi.org/10.13422/j.cnki.syfxj.20200101>.
30. Ping J, Lingling D, Xue W, Xiao L. Study on effect difference between Guizhi decoction and Huanglianjiedu decoction on immune-inflammatory factors and myocardial basement membrane in spontaneous diabetic rats [in Chinese]. *World Journal of Integrated Traditional and Western Medicine*. 2015;10(7):999–1002. <https://doi.org/10.13935/j.cnki.sjzx.150736>.
31. Ma'ayan A. Complex systems biology. *J R Soc Interface*. 2017;14(134):20170391. <https://doi.org/10.1098/rsif.2017.0391>.
32. Li S, Zhang B. Traditional Chinese medicine network pharmacology: theory, methodology and application. *Chin J Nat Med*. 2013;11(2):110–20. [https://doi.org/10.1016/S1875-5364\(13\)60037-0](https://doi.org/10.1016/S1875-5364(13)60037-0).
33. Lu WW, Qiu YJ, Fan XF, Yu GY, Wu GL. Mechanism of Huangqi Guizhi Wuwu decoction in treatment of rheumatoid arthritis based on UPLC-LTQ-Orbitrap-MS, network pharmacology, and cell experiment. *Zhongguo Zhong Yao Za Zhi*. 2021;46(24):6454–64. <https://doi.org/10.19540/j.cnki.cjmm.20210902.703>.
34. Chen T, Shi Y, Shi W. Huangqi Guizhi Wuwu decoction in peripheral neurotoxicity treatment using network pharmacology and molecular docking. *Medicine (Baltimore)*. 2022;101(42):e31281. <https://doi.org/10.1097/MD.00000000000031281>.
35. Pan B, Xia Y, Fang S, et al. Integrated network pharmacology and serum metabolomics approach decipher the anti-colon cancer mechanisms of Huangqi Guizhi Wuwu decoction. *Front Pharmacol*. 2022;13:1043252. <https://doi.org/10.3389/fphar.2022.1043252>.
36. Becker R. *The new S language*: CRC Press; 2018. <https://doi.org/10.1201/9781351074988>.
37. Wu T, Hu E, Xu S, et al. A universal enrichment tool for interpreting omics data. *Innovation (Camb)*. 2021;2(3):100141. <https://doi.org/10.1016/j.xinn.2021.100141>.
38. Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. *Nucleic Acids Res*. 2000;28(1):27–30. <https://doi.org/10.1093/nar/28.1.27>.
39. Kanehisa M. Toward understanding the origin and evolution of cellular organisms. *Protein Sci*. 2019;28(11):1947–51. <https://doi.org/10.1002/pro.3715>.
40. Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M. KEGG: integrating viruses and cellular organisms. *Nucleic Acids Res*. 2021;49(D1):D545–51. <https://doi.org/10.1093/nar/gkaa970>.
41. Szklarczyk D, Morris JH, Cook H, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. *Nucleic Acids Res*. 2017;45(D1):D362–8. <https://doi.org/10.1093/nar/gkw937>.
42. Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. *BMC Syst Biol*. 2014;8(Suppl 4):S11. <https://doi.org/10.1186/1752-0509-8-S4-S11>.
43. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multi-threading. *J Comput Chem*. 2010;31(2):455–61. <https://doi.org/10.1002/jcc.21334>.
44. Han J, Kim HJ, Lee SC, et al. Structure-Based Rational Design of a Toll-like Receptor 4 (TLR4) Decoy Receptor with High Binding Affinity for a Target Protein. *PLoS ONE*. 2012;7(2):e30929. <https://doi.org/10.1371/journal.pone.0030929>.
45. Fischmann TO, Hruza A, Niu XD, et al. Structural characterization of nitric oxide synthase isoforms reveals striking active-site conservation. *Nat Struct Biol*. 1999;6(3):233–42. <https://doi.org/10.1038/6675>.
46. Hinck AP, Archer SJ, Qian SW, et al. Transforming growth factor beta 1: three-dimensional structure in solution and comparison with the X-ray structure of transforming growth factor beta 2. *Biochemistry*. 1996;35(26):8517–34. <https://doi.org/10.1021/bi9604946>.
47. Ghosh G, van Duynne G, Ghosh S, Sigler PB. Structure of NF- κ B p50 homodimer bound to a κ B site. *Nature*. 1995;373(6512):303–10. <https://doi.org/10.1038/373303a0>.
48. Basse N, Kaar JL, Settanni G, Joerger AC, Rutherford TJ, Fersht AR. Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant. *Chem Biol*. 2010;17(1):46–56. <https://doi.org/10.1016/j.chembiol.2009.12.011>.
49. Lubetsky JB, Dios A, Han J, et al. The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. *J Biol Chem*. 2002;277(28):24976–82. <https://doi.org/10.1074/jbc.M203220200>.
50. Liddle J, Atkinson FL, Barker MD, Carter PS, Curtis NR, Davis RP, et al. Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor. *Bioorg Med Chem Lett*. 2011;21(20):6188–94. <https://doi.org/10.1016/j.bmcl.2011.07.082>.
51. Nuti E, Cantelmo AR, Gallo C, et al. N-O-isopropyl Sulfonylamido-based Hydroxamates as matrix metalloproteinase inhibitors: hit selection and in vivo antiangiogenic activity. *J Med Chem*. 2015;58(18):7224–40. <https://doi.org/10.1021/acs.jmedchem.5b00367>.
52. Gampe RT, Montana VG, Lambert MH, et al. Asymmetry in the PPAR- γ /RXR α crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. *Mol Cell*. 2000;5(3):545–55. [https://doi.org/10.1016/S1097-2765\(00\)80448-7](https://doi.org/10.1016/S1097-2765(00)80448-7).
53. Tamanini E, Buck IM, Chessari G, et al. Discovery of a potent Nonpeptidomimetic, small-molecule antagonist of cellular inhibitor of apoptosis protein 1 (cIAP1) and X-linked inhibitor of apoptosis protein (XIAP). *J Med Chem*. 2017;60(11):4611–25. <https://doi.org/10.1021/acs.jmedchem.6b01877>.
54. Rowlinson SW, Kiefer JR, Prusakiewicz JJ, et al. A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385. *J Biol Chem*. 2003;278(46):45763–9. <https://doi.org/10.1074/jbc.M305481200>.
55. Bai L, Zhou H, Xu R, Zhao Y, Chinnaswamy K, McEachern D, et al. A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo. *Cancer Cell*. 2019;36(5). <https://doi.org/10.1016/j.ccell.2019.10.002>.
56. He MM, Smith AS, Oslob JD, et al. Small-molecule inhibition of TNF- α . *Science*. 2005;310(5750):1022–5. <https://doi.org/10.1126/science.1116304>.
57. Li SX, Huang S, Bren N, et al. Ligand-binding domain of an α 7 nicotinic receptor chimera and its complex with agonist. *Nat Neurosci*. 2011;14(10):1253–9. <https://doi.org/10.1038/nn.2908>.
58. Camps M, Ruckle T, Ji H, et al. Blockade of PI3K γ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. *Nat Med*. 2005;11(9):936–43. <https://doi.org/10.1038/nm1284>.
59. Thanos CD, DeLano WL, Wells JA. Hot-spot mimicry of a cytokine receptor by a small molecule. *Proc Natl Acad Sci U S A*. 2006;103(42):15422–7. <https://doi.org/10.1073/pnas.0607058103>.
60. Wu WJ, Voegtli WC, Sturgis HL, Dizon FP, Vigers GPA, Brandhuber BJ. Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition. *PLoS One*. 2010;5(9):e12913. <https://doi.org/10.1371/journal.pone.0012913>.
61. Percie du Sert N, Hurst V, Ahluwalia A, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. *PLoS Biol*. 2020;18(7):e3000410. <https://doi.org/10.1371/journal.pbio.3000410>.
62. Ho KV, Schreiber KL, Vu DC, et al. Black walnut (*Juglans nigra*) extracts inhibit Proinflammatory cytokine production from lipopolysaccharide-stimulated human Promonocytic cell line U-937. *Front Pharmacol*. 2019;10:1059. <https://doi.org/10.3389/fphar.2019.01059>.
63. De Simone R, Ajmone-Cat MA, Carnevale D, Minghetti L. Activation of α 7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures. *J Neuroinflammation*. 2005;2(1):4. <https://doi.org/10.1186/1742-2094-2-4>.
64. Zhang Q, Lu Y, Bian H, Guo L, Zhu H. Activation of the α 7 nicotinic receptor promotes lipopolysaccharide-induced conversion of M1 microglia to M2. *Am J Transl Res*. 2017;9(3):971–85.
65. Egea J, Buendia I, Parada E, Navarro E, León R, Lopez MG. Anti-inflammatory role of microglial α 7 nAChRs and its role in neuroprotection. *Biochem Pharmacol*. 2015;97(4):463–72. <https://doi.org/10.1016/j.bcp.2015.07.032>.
66. Fu S, Zhou Y, Hu C, Xu Z, Hou J. Network pharmacology and molecular docking technology-based predictive study of the active ingredients and potential targets of rhubarb for the treatment of diabetic nephropathy. *BMC Complementary Medicine and Therapies*. 2022;22(1):210. <https://doi.org/10.1186/s12906-022-03662-6>.

67. Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. *Nature*. 2000;405(6785):458–62. <https://doi.org/10.1038/35013070>.
68. Kalkman HO, Feuerbach D. Antidepressant therapies inhibit inflammation and microglial M1-polarization. *Pharmacol Ther*. 2016;163:82–93. <https://doi.org/10.1016/j.pharmthera.2016.04.001>.
69. Li X, Hua JY, Jiang P, Long YJ, Fang MD, Hua YC. Effect of Guizhi decoction ((symbols; see text)) on heart rate variability and regulation of cardiac autonomic nervous imbalance in diabetes mellitus rats. *Chin J Integr Med*. 2014;20(7):524–33. <https://doi.org/10.1007/s11655-014-1861-z>.
70. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. *Nat Rev Immunol*. 2008;8(12):958–69. <https://doi.org/10.1038/nri2448>.
71. Malyshev I, Malyshev Y. Current concept and update of the macrophage plasticity concept: intracellular mechanisms of reprogramming and M3 macrophage “switch” phenotype. *Biomed Res Int*. 2015;2015:341308. <https://doi.org/10.1155/2015/341308>.
72. Arranz A, Doxaki C, Vergadi E, et al. Akt1 and Akt2 protein kinases differentially contribute to macrophage polarization. *Proc Natl Acad Sci U S A*. 2012;109(24):9517–22. <https://doi.org/10.1073/pnas.1119038109>.
73. Wu J, Zhang L, Shi J, et al. Macrophage phenotypic switch orchestrates the inflammation and repair/regeneration following acute pancreatitis injury. *EBioMedicine*. 2020;58:102920. <https://doi.org/10.1016/j.ebiom.2020.102920>.
74. Chen L, Zhang J, Zou Y, et al. Kdm2a deficiency in macrophages enhances thermogenesis to protect mice against HFD-induced obesity by enhancing H3K36me2 at the Pparg locus. *Cell Death Differ*. 2021;28(6):1880–99. <https://doi.org/10.1038/s41418-020-00714-7>.
75. Tong Y, Yu Z, Chen Z, et al. The HIV protease inhibitor Saquinavir attenuates sepsis-induced acute lung injury and promotes M2 macrophage polarization via targeting matrix metalloproteinase-9. *Cell Death Dis*. 2021;12(1):67. <https://doi.org/10.1038/s41419-020-03320-0>.
76. Zheng Q, Hou J, Zhou Y, Yang Y, Cao X. Type I IFN-inducible downregulation of MicroRNA-27a feedback inhibits antiviral innate response by upregulating Siglec1/TRIM27. *J Immunol*. 2016;196(3):1317–26. <https://doi.org/10.4049/jimmunol.1502134>.
77. Jiang B, Zhu SJ, Xiao SS, Xue M. MiR-217 inhibits M2-like macrophage polarization by suppressing secretion of Interleukin-6 in ovarian Cancer. *Inflammation*. 2019;42(5):1517–29. <https://doi.org/10.1007/s10753-019-01004-2>.
78. Bao L, Li X. MicroRNA-32 targeting PTEN enhances M2 macrophage polarization in the glioma microenvironment and further promotes the progression of glioma. *Mol Cell Biochem*. 2019;460(1–2):67–79. <https://doi.org/10.1007/s11010-019-03571-2>.
79. Liu S, Lu C, Liu Y, et al. Hyperbaric oxygen alleviates the inflammatory response induced by LPS through inhibition of NF- κ B/MAPKs-CCL2/CXCL1 signaling pathway in cultured astrocytes. *Inflammation*. 2018;41(6):2003–11. <https://doi.org/10.1007/s10753-018-0843-2>.
80. Wazea SA, Wadie W, Bahgat AK, El-Abhar HS. Galantamine anti-colic effect: role of alpha-7 nicotinic acetylcholine receptor in modulating Jak/STAT3, NF- κ B/HMGB1/RAGE and p-AKT/Bcl-2 pathways. *Sci Rep*. 2018;8(1):5110. <https://doi.org/10.1038/s41598-018-23359-6>.
81. Liu C, Liu S, Xiong L, et al. Genistein-3'-sodium sulfonate attenuates Neuroinflammation in stroke rats by Down-regulating microglial M1 polarization through α 7nAChR-NF- κ B signaling pathway. *Int J Biol Sci*. 2021;17(4):1088–100. <https://doi.org/10.7150/ijbs.56800>.
82. Chang NC, Yeh CT, Lin YK, et al. Garcinol attenuates lipoprotein(a)-induced oxidative stress and inflammatory cytokine production in ventricular Cardiomyocyte through α 7-nicotinic acetylcholine receptor-mediated inhibition of the p38 MAPK and NF- κ B signaling pathways. *Antioxidants (Basel)*. 2021;10(3):461. <https://doi.org/10.3390/antiox10030461>.
83. Han Z, Shen F, He Y, et al. Activation of α -7 nicotinic acetylcholine receptor reduces ischemic stroke injury through reduction of pro-inflammatory macrophages and oxidative stress. *PLoS One*. 2014;9(8):e105711. <https://doi.org/10.1371/journal.pone.0105711>.
84. Aripova N, Duryee MJ, Hunter CD, et al. Peptidyl arginine deiminase expression and macrophage polarization following stimulation with citrullinated and malondialdehyde-acetaldehyde modified fibrinogen. *Int Immunopharmacol*. 2022;110:109010. <https://doi.org/10.1016/j.intimp.2022.109010>.
85. Liu X, Su J, Zhou H, et al. Collagen VI antibody reduces atherosclerosis by activating monocyte/macrophage polarization in ApoE $^{-/-}$ mice. *Int Immunopharmacol*. 2022;111:109100. <https://doi.org/10.1016/j.intimp.2022.109100>.
86. Lee JH, Lee SH, Lee EH, et al. SCAP deficiency facilitates obesity and insulin resistance through shifting adipose tissue macrophage polarization. *J Adv Res*. 2022;S2090-1232(22):00124-2. <https://doi.org/10.1016/j.jare.2022.05.013>.
87. Mo Y, Kang H, Bang JY, et al. Intratracheal administration of mesenchymal stem cells modulates lung macrophage polarization and exerts anti-asthmatic effects. *Sci Rep*. 2022;12(1):11728. <https://doi.org/10.1038/s41598-022-14846-y>.
88. Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? *Nat Rev Neurol*. 2021;17(3):157–72. <https://doi.org/10.1038/s41582-020-00435-y>.
89. Wanna L, Huilin S, Huimin L, et al. Therapeutic mechanism of Huangqi Guizhi Wuwutang on rheumatoid arthritis [inChinese]. *Chin J Exp Tradit Med Formulae*. 2022;28(9):9–15. <https://doi.org/10.13422/j.cnki.syfxj.20220607>.
90. Yin G, Dingguo Y. Effects of modified huangqi guizhi wuwu decoction on hemodynamics and levels of Lp-PLA2 and Hcy in patients with Type 2 diabetes mellitus complicated with lower extremity atherosclerotic disease [inChinese]. *Journal of Guizhou Medical University*. 2021;46(9):1059-1064+1069. <https://doi.org/10.19367/j.cnki.2096-8388.2021.09.012>.
91. Wang Y, Chen T, Yang C, et al. Huangqi Guizhi Wuwu decoction improves arthritis and pathological damage of heart and lung in TNF-Tg mice. *Front Pharmacol*. 2022;13:871481. <https://doi.org/10.3389/fphar.2022.871481>.
92. Li Y, Yao J, Han C, et al. Quercetin, inflammation and immunity. *Nutrients*. 2016;8(3):167. <https://doi.org/10.3390/nu8030167>.
93. Pérez-Cano FJ, Castell M. Flavonoids, inflammation and immune system. *Nutrients*. 2016;8(10):E659. <https://doi.org/10.3390/nu8100659>.
94. Yang JH, Kim SC, Shin BY, et al. O-methylated flavonol isorhamnetin prevents acute inflammation through blocking of NF- κ B activation. *Food Chem Toxicol*. 2013;59:362–72. <https://doi.org/10.1016/j.fct.2013.05.049>.
95. Kim KA, Lee IA, Gu W, Hyam SR, Kim DH. β -Sitosterol attenuates high-fat diet-induced intestinal inflammation in mice by inhibiting the binding of lipopolysaccharide to toll-like receptor 4 in the NF- κ B pathway. *Mol Nutr Food Res*. 2014;58(5):963–72. <https://doi.org/10.1002/mnfr.201300433>.
96. Dong J, Zhang X, Zhang L, et al. Quercetin reduces obesity-associated ATM infiltration and inflammation in mice: a mechanism including AMPK α 1/SIRT1. *J Lipid Res*. 2014;55(3):363–74. <https://doi.org/10.1194/jlr.M038786>.
97. Tian H, Lin S, Wu J, et al. Kaempferol alleviates corneal transplantation rejection by inhibiting NLRP3 inflammasome activation and macrophage M1 polarization via promoting autophagy. *Exp Eye Res*. 2021;208:108627. <https://doi.org/10.1016/j.exer.2021.108627>.
98. Chen F, Hu M, Shen Y, et al. Isorhamnetin promotes functional recovery in rats with spinal cord injury by abating oxidative stress and modulating M2 macrophages/microglia polarization. *Eur J Pharmacol*. 2021;895:173878. <https://doi.org/10.1016/j.ejphar.2021.173878>.
99. Liu R, Hao D, Xu W, et al. β -Sitosterol modulates macrophage polarization and attenuates rheumatoid inflammation in mice. *Pharm Biol*. 2019;57(1):161–8. <https://doi.org/10.1080/13880209.2019.1577461>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.